Determination by LC-MS/MS of colistins A and B in plasma and ultrafiltrate from critically ill patients undergoing continuous venovenous hemodiafiltration

Therapeutic Drug Monitoring

Volumn 36, Issue 2, 2014, Pages 182-191

  Leporati, Marta ^a   Bua, Rosaria Ornella ^b   Mariano, Filippo ^c   Carignano, Paola ^d   Stella, Maurizio ^d   Biancone, Luigi ^b   Vincenti, Marco ^a,b  

^a Centro Regionale Antidoping e di Tossicologia A Bertinaria   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c CTO HOSPITAL   (Italy)

^d Dipartimento di Chirurgia Plastica Centro Grandi Ustionati Azienda Ospedaliera Città della Scienza e della Salute di Torino   (Italy)

Author keywords

Colistin; CVVHDF; Dialysis; LC MS MS; Ultrafiltrate

Indexed keywords

COLISTIN; COLISTIN B; COLISTINS A; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; COLISTIN A, PAENIBACILLUS POLYMYXA JB05-01-1; COLISTIN B, PAENIBACILLUS POLYMYXA JB05-01-1; COLISTINMETHANESULFONIC ACID;

ARTICLE; BLOOD FLOW; CONTINUOUS HEMODIAFILTRATION; CRITICALLY ILL PATIENT; DIAGNOSTIC TEST ACCURACY STUDY; DIALYSIS; DRUG CLEARANCE; DRUG DETERMINATION; EFFLUENT; FLOW RATE; HUMAN; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; NORMAL HUMAN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; ULTRAFILTRATION; VALIDATION STUDY; ANALOGS AND DERIVATIVES; BLOOD; CRITICAL ILLNESS; HEMODIAFILTRATION; MASS SPECTROMETRY; PROCEDURES;

ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, LIQUID; COLISTIN; CRITICAL ILLNESS; HEMODIAFILTRATION; HUMANS; LIMIT OF DETECTION; MASS SPECTROMETRY; SENSITIVITY AND SPECIFICITY;

EID: 84897040595     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182a8997c     Document Type: Article

References (32)

1. Koyama Y, Kurosasa A, Tsuchiya A, et al. A new antibiotic "colistin" produced by spore-forming soil bacteria. J Antibiot (Tokyo). 1950;3:457-458
2. Li J, Nation RL, Milne RW, et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents. 2005;25:11-25
3. Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009; 22:535-543
4. Gobin P, Lemaître F, Marchand S, et al. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-Tandem mass spectrometry. Antimicrob Agents Chemother. 2010;54:1941-1948
5. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother. 2009;53: 3430-3436
6. Koch-Weser J, Sidel VW, Friedman EB. Adverse effects of sodium colistimethate. Manifestation and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970;72:857-868
7. Bosso JA, Liptak CA, Seilheimer DK. Toxicity of colistin in cystic fibrosis patients. Ann Pharmacother. 1991;25:1168-1170
8. Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009;48:1724-1728
9. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulphate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann Pharmacother. 1999;33:960-967
10. Falagas ME, Kasiakou SK. Toxicity of polymyxins: A systematic review of the evidence from old and recent studies. Crit Care. 2006;10:R27
11. Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41:1159-1166
12. Reed MD, Stern RC, O'Riordan MA. The pharmacokinetics of colistin in patient with cystic fibrosis. J Clin Pharmacol. 2001;41:645-654
13. Li JR, Milne W, Nation RL, et al. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother. 2004;53: 837-840
14. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically-ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284-3294
15. Renard L, Sanders P, Laurentie M. Pharmacokinetics of colistin sulfate administered by intravenous and intramuscular routes in the calf. Ann Rech Vet. 1991;22:387-394
16. Thomas TA, Broun EC, Abildskov KM, et al. High performance liquid chromatography-mass spectrometry assay for polymyxin in B1 and B2 in human plasma. Ther Drug Monit. 2012;34:398-405
17. Cheng C, Liu S, Xiao D, et al. LC-MS/MS method development and validation for the determination of polymyxins and vancomycin in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878: 2831-2838
18. Ma Z, Wang J, Gerber JP, et al. Determination of colistin in human plasma, urine and other biological samples using LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;862:205-212
19. Markou N, Fousteri M, Markantonis SL, et al. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: An observational study. J Antimicrob Chemother. 2012;67:2459-2462
20. Jansson B, Karvenen M, Cars O, et al. Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC-MS/MS. J Pharm Biomed Anal. 2009;49:760-767
21. Peters FT, Drummer OH, Musshoff F. Validation of new methods. Forensic Sci Int. 2007;165:216-224
22. Orwa JA, Govaerts C, Gevers K, et al. Study of the stability of polymyxins B1, E1 and E2 in aqueous solution using liquid chromatography and mass spectrometry. J Pharm Biomed Anal. 2002;29:203-212
23. European Medicines Agency; Committee for Medicinal Products for Human Use (CHMP). Guideline on Bioanalytical Method Validation. 2011. EMEA/CHMP/EWP/192217/2009
24. Morgera S, Schneider M, Slowinski T, et al. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med. 2009;37:2018-2024
25. Mariano F, Tedeschi L, Morselli M, et al. Normal citratemia and metabolic tolerance of citrate anticoagulation for hemodiafiltration in severe septic shock burn patients. Intensive Care Med. 2010;36:1735-1743
26. Mariano F, Morselli M, Bergamo D, et al. Blood and ultrafiltrate dosage of citrate as a useful and routine tool during continuous venovenous haemodiafiltration in septic shock patients. Nephrol Dial Transplant. 2011;26:3882-3888
27. Li J, Nation RL, Turnidge JD, et al. Colistin: The re-emerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6:589-601
28. Xu Y, Tian X, Ren C, et al. Analysis of colistin A and B in fishery products by ultra performance liquid chromatography with positive electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;899:14-20
29. WADA Technical Document - TD2010IDCR [WADA Web site]. Available at: Http://www.wada-ama.org/Documents/World-Anti-Doping- Program/WADP-IS- Laboratories/Technical-Documents/WADA- TD2010IDCRv1.0- Identification%20Criteria%20for%20Qualitative% 20Assays-May%2008%202010-EN.doc. pdf. Accessed 2013
30. Heilmann K, Keller T. Polysulfone: The development of a membrane for convective therapies. Contrib Nephrol. 2011;175:15-26
31. Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: Population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother. 2012;56:4241-4249
32. Leypoldt JK. Fouling of ultrafiltration and hemodialysis membranes by plasma proteins. Blood Purif. 1994;12:285-291.